Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BURKIMAB-14: Rituximab and Chemotherapy in Adult Burkitt Lymphoma/Leukemia
NCT05049473Phase 2Unknown
- Sponsor
- Fundación PETHEMA
- Start
- Jan 2014
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in Burkitt lymphoma (BL), Mature B-cell acute lymphoblastic leukemia, high grade B-cell lymphoma (HGBCL), sponsored by Fundación PETHEMA. Status: unknown.
02
Drugs
rituximab
03
Conditions
Burkitt lymphoma (BL)Mature B-cell acute lymphoblastic leukemiahigh grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT05049473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05049473.